CTLA-4 blockade: therapeutic potential in cancer treatments

Ahmad A Tarhini, Fatima Iqbal, Ahmad A Tarhini, Fatima Iqbal

Abstract

Enhancing or prolonging T-cell activation by monoclonal antibodies (mAbs) blocking negative signaling receptors such as CTLA4 is one approach to overcoming tumor-induced immune tolerance. Ipilimumab and tremelimumab inhibit CTLA4, prolonging antitumor immune responses and leading to durable anti-tumor effects. Treatment with these mAbs has demonstrated clinically important and durable tumor responses and disease control rates in patients with unresectable advanced melanoma. Durable objective responses have been reported across a spectrum of doses and schedules, with relative safety in this patient population. Although the phase III tremelimumab melanoma study was closed for "futility", the 1-year survival rate of >50% for tremelimumab and the median survival of 11.7 months (compared with 10.7 months for chemotherapy) are notable. Results of the phase III studies testing CTLA4-blockade with ipilimumab are eagerly anticipated. The further development of these agents includes testing in the neoadjuvant melanoma setting (ipilimumab) as well the adjuvant high-risk melanoma setting (ipilimumab). Future progress with CTLA-4 blockade therapy will also likely come from the use of combinations of agents that target several critical regulatory pathways of the immune system and modulate the immune response in the host in a synergistic and controlled fashion.

Keywords: cancer treatment; ipilimumab; monoclonal antibodies; tremelimumab.

References

    1. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23:8968–8977.
    1. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194:863–869.
    1. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709–760.
    1. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5:471–484.
    1. Tarhini AA, Kirkwood JM, AM K. Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers. Expert Opin Drug Discov. 2009;4(5):587–603.
    1. Khattri R, Auger JA, Griffin MD, et al. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J Immunol. 1999;162:5784–5791.
    1. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541–547.
    1. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–988.
    1. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T-cell costimulation. Annu Rev Immunol. 1996;14:233–258.
    1. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T-cells to stimulation. J Exp Med. 1995;182:459–465.
    1. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12:1005–1016.
    1. Linsley PS, Greene JL, Brady W, et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994;1:793–801.
    1. Paterson AM, Vanguri VK, Sharpe AH. SnapShot: B7/CD28 costimulation. Cell. 2009;137:974–974.
    1. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174:561–569.
    1. Alegre ML, Shiels H, Thompson CB, et al. Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol. 1998;161:3347–3356.
    1. McCoy KD, Le Gros G. The role of CTLA-4 in the regulation of T-cell immune responses. Immunol Cell Biol. 1999;77:1–10.
    1. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity. 2002;16:23–35.
    1. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002;3:611–618.
    1. Kwon ED, Hurwitz AA, Foster BA, et al. Manipulation of T-cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A. 1997;94:8099–8103.
    1. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–1736.
    1. Kwon ED, Foster BA, Hurwitz AA, et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA–4) blockade immunotherapy. Proc Natl Acad Sci U S A. 1999;96:15074–15079.
    1. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol. 2005;175:7746–7754.
    1. Canniff PC, Donovan CB, Burkwit JJ, et al. CP-675,205 anti-CTLA4 antibody clinical candidate enhances IL-2 production in cancer patient T-cells in vitro regardless of tumor type or stage of disease [poster], [abstract 709]. Orlando, FL. 95th Annual Meeting of the American Association for Cancer Research; 2004.
    1. Hanson DC, Canniff PC, Primiano MJ, et al. Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206 [poster], [abstract 3802]. Orlando, FL. 95th Annual Meeting of the American Association for Cancer Research; 2004.
    1. Camacho LH, Ribas A, Glaspy JA, et al. Phase I clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients with advanced solid malignancies [oral presentation] [abstract 2005] J Clin Oncol 20042214s (Suppl; abstract 2505).
    1. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest. 1970;49:673–680.
    1. Ribas A, Bozon VA, Lopez-Berestein G, et al. Phase I trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma. J Clin Oncol. 2005;23(Suppl):716s. (abstr 7524).
    1. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645–2668.
    1. Wang E, Kang D, Wang C. Relationship between pharmacokinetics and safety of tremelimumab in patients with melanoma. J Clin Oncol. 2009;27(Suppl):15s. (abstr 3049).
    1. Ribas A, Antonia S, Sosman J, et al. Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma [oral] J Clin Oncol. 2007;25(Suppl):18S. (abstr 3000).
    1. Chung KY, Gore I, Fong L, et al. A phase II study of tremelimumab (CP-675,206), an anti-CTLA4 monoclonal antibody, in patients with refractory metastatic colorectal cancer [oral presentation]. Boston, MA. International Society for Biological Therapy of Cancer 22nd Annual Meeting; 2007.
    1. Zatloukal P, Heo DS, Park K. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) J Clin Oncol. 2009;27(Suppl):15s. (abstr 8071).
    1. Vonderheide RH, LoRusso PM, Khalil M. Tremelimumab in combination with exemestane as novel immunotherapy for patients with advanced breast cancer. J Clin Oncol. 2009;27(Suppl):15s. (abstr 3034).
    1. Gordon MS, Stein M, Shannon P. Phase I dose escalation trial of tremelimumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) J Clin Oncol. 2009;27(Suppl):15s. (abstr 5115).
    1. Small E, Weinberg V, Kavanagh B. Combination immunotherapy with GM-CSF and ipilimumab (anti-CTLA4 antibody) in patients with metastatic hormone refractory prostate cancer. 2007 Prostate Cancer Symposium; (abstr 49 2007).
    1. Slovin S, Beer T, Higano C. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) J Clin Oncol. 2009;27(Suppl):15s. (abstr 5138).
    1. Gomez-Navarro J, Sharma A, Bozon V, et al. Dose and schedule selection for the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in patients (pts) with metastatic melanoma. J Clin Oncol. 2006;24(Suppl):460s. (abstr 8032).
    1. Gomez-Navarro J, Antonia S, Sosman J, et al. Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study. [poster] J Clin Oncol. 2007;25(Suppl):18s. (abstr 8524).
    1. Comin-Anduix B, Lee Y, Jalil J, et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med. 2008;6:22.
    1. Reuben JM, Lee BN, Shen DY, et al. Therapy with human monoclonal anti-CTLA-4 antibody, CP-675,206, reduces regulatory T-cells and IL-10 production in patients with advanced malignant melanoma (MM) [oral presentation] J Clin Oncol. 2005;23:16S. (Suppl:abstract 7505).
    1. Kirkwood JM, Lorigan P, Hersey P, et al. A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma [poster and discussion] J Clin Oncol. 2008;26(Suppl) (abstr 9023).
    1. Chung KY, Dorazio P, Pavlov D, et al. Survival of patients with refractory metastatic colorectal cancer treated with tremelimumab (CP-675,206), an anti-CTLA4 monoclonal antibody in a phase II study [poster] [abstract 351]. Presented at the 2008 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology.
    1. Ribas A, Comin-Anduix B, Jalil J, et al. Combination of dendritic cell (DC) vaccination with CTLA4 blockade in patients (pts) with metastatic melanoma: a phase 1 clinical trial [oral] [abstract 2537]. San Diego, CA. Presented at the American Association for Cancer Research Symposium; April 12–16, 2008.
    1. Tarhini AA, Moschos SS, Schlesselman JJ, et al. Phase II trial of combination biotherapy of high-dose interferon alfa-2b and tremelimumab for recurrent inoperable stage III or stage IV melanoma. J Clin Oncol. 2008;26(Suppl) (abstr 9009).
    1. Underhill C, Millward M, Lobb S. Phase I dose escalation trial of tremelimumab (CP-675,206) administered in combination with PF-3512676 in patients with melanoma or other advanced cancers. J Clin Oncol. 2009;27(Suppl):15s. (abstr 3046).
    1. Ribas A, Hauschild A, Kefford R, et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma [oral] J Clin Oncol. 2008 May 26;20(Suppl) (abstr LBA9011).
    1. Wallis N, Bulanhagui C, Dorazio PC, et al. Safety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer [poster] J Clin Oncol. 2008 May 26;20(Suppl) (abstr 3040).
    1. Straatsma BR, Nusinowitz S, Young TA, et al. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am J Ophthalmol. 2007;143:958–969.
    1. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T lymphocyte antigen-4. J Clin Oncol. 2005;23:6043–6053.
    1. Small EJ, Tchekmedyian NS, Rini BI, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:1810–1815.
    1. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100:8372–8377.
    1. Dai D, Wu S, Parker M. Model-based evaluation of ipilimumab dose regiment in patients with advanced melanoma. J Clin Oncol. 2008 May;20(Suppl 26) (abstr 9073).
    1. Thompson J, Berman D, Siegal J, et al. Effect of prior treatment status on the efficacy and safety of ipilimumab monotherapy in treatment-naive and previously treated patients with advanced melanoma. Proc Am Soc Clin Oncol. 2008;26 (abstr 9055).
    1. Tchekmedyian S, Glasby J, Korman A, et al. MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma. Proc Am Soc Clin Oncol. 2002;21 (abstr 56).
    1. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008;105:3005–3010.
    1. Hamid O. Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study. J Clin Oncol. 2008;26(Suppl) (abstr 9025).
    1. Hersh E, Weber J, Powderly J, et al. Long-term survival of patients with advanced melanoma treated with ipilimumab with or without dacarbazine. J Clin Oncol. 2009;27(Suppl):15s. (abstr 9038).
    1. Fischkoff S, Hersh E, Weber J, et al. Durable responses and long-term progression-free survival observed in a phase ii study of mdx-010 alone or in combination with dacarbazine (dtic) in metastatic melanoma. J Clin Oncol. 2005;23(Suppl):16s. (abstr 7525).
    1. Beer T, Slovin S, Higano C, et al. Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC) J Clin Oncol. 2008;26(Suppl) (abstr 5004).
    1. Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunotherapy. 2005;28:593–598.
    1. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunotherapy. 2007;30:825–830.
    1. Weber J. Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma. J Clin Oncol. 2005;26(Suppl) (abstr 9010).
    1. Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunotherapy. 2006;29:455–463.
    1. Wolchok J, de Pril V, Linette G, et al. Efficacy of ipilimumab 10 mg/kg in advanced melanoma patients with good and poor prognostic factors. J Clin Oncol. 2009;27(Suppl):15s. (abstr 9036).
    1. Smylie M, Francis S, Neyns B, et al. Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels. J Clin Oncol. 2009;27(Suppl):15s. (abstr 9041).
    1. O’Day S, Weber J, Lebbe C. Ipilimumab treatment may be associated with a long-term survival benefit: 18-month survival rate of patients with advanced melnaoma treated with 10 mg/kg ipilimumab in three phase ii clinical trials. J Clin Oncol. 2009;27(Suppl):15s. (abstr 9033).
    1. Weber J, Sarnaik A, Targan S, et al. Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multipeptide vaccine for resected stages IIIC and IV melanoma. J Clin Oncol. 2009;27(Suppl):15s. (abstr 9023).
    1. Lutzky J, Wolchok J, Hamid O, et al. Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol. 2009;27(Suppl):15s. (abstr 9034).
    1. Chen B, Phillips J, Greenbaum M, et al. Efficacy of anti-CTLA-4 anti-body in the SA1N tumor model when combined with dexamethasone 98th AACR Annual Meeting, AACR Meeting AbstractsApr 2007: Abstract 2202.
    1. Weber J. Safety and efficacy of iplimumab with or without prophylactic budesonide in the treatment-naive and preveiously treated patients with advanced melanoma. J Clin Oncol. 2008;26(Suppl) (abstr 9010).
    1. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26:527–534.
    1. Korn E, Liu PY, Lee S, et al. Meta-analysis of phase II cooperative group trials in metastatic stage iv melanoma: determining progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26:527–534.
    1. Weber JS, Hersh EM, Yellin M, et al. The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma [poster] J Clin Oncol. 2007;25(Suppl):477s. (abstr 8523).
    1. Weber JS. The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies. Melanoma Res. 2006;16:379–383.
    1. Tatsumi T, Kierstead LS, Ranieri E, et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T-cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med. 2002;196:619–628.
    1. Tatsumi T, Herrem CJ, Olson WC, et al. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res. 2003;63:4481–4489.
    1. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190:355–366.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться